Welcome to our dedicated page for Vyne Therapeutics SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for VYNE Therapeutics Inc. (VYNE) provides direct access to the company’s regulatory disclosures as a Nasdaq-listed clinical-stage biopharmaceutical issuer. These documents include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, which together outline VYNE’s financial condition, risk factors, clinical programs and material corporate events.
Through its filings, VYNE describes its focus on developing differentiated BET inhibitor therapies for chronic inflammatory and immune-mediated conditions, including programs such as the oral BD2-selective BET inhibitor VYN202 and the topical pan-BD BET inhibitor repibresib gel. Periodic reports discuss research and development spending, general and administrative expenses, royalty revenue from its agreement with LEO Pharma A/S for Finacea® foam, and cash runway expectations under various operating assumptions.
Current reports on Form 8-K highlight specific developments that may be important to investors. Examples include disclosures of quarterly and annual financial results, clinical trial updates that are furnished as exhibits, and governance changes such as director resignations. A notable Form 8-K filed on December 17, 2025 describes VYNE’s entry into an Agreement and Plan of Merger and Reorganization with Yarrow Bioscience, Inc. and a merger subsidiary. That filing summarizes the structure of the all-stock merger, the expected pro forma ownership split, planned stockholder approvals, and conditions to closing, as well as related financing arrangements and support agreements.
Other 8-K filings detail the company’s annual meeting voting results and confirm its continued listing of common stock on The Nasdaq Stock Market LLC under the symbol VYNE. Together, these filings allow readers to review how VYNE reports material events, manages its capital structure and describes its strategic review and merger plans.
On this page, AI-powered tools can help interpret complex sections of lengthy filings by highlighting key points, summarizing risk factor themes and explaining the implications of items such as merger agreements, clinical program disclosures and changes in governance. Users can quickly locate information about VYNE’s quarterly performance in Forms 10-Q, its annual overview and risk disclosures in Form 10-K, and specific events reported on Forms 8-K, while using AI-generated summaries as a guide to the underlying regulatory text.
VYNE Therapeutics Inc. Chief Financial Officer Zeronda Tyler reported a Form 4 disclosing a non‑derivative disposition on 09/30/2025. The filing shows 3,420 shares of common stock were disposed of at a price of $0.335 per share. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting of restricted stock units. After the reported transaction, the reporting person beneficially owns 111,653 shares, held in a direct ownership form. The Form 4 is signed by an attorney‑in‑fact and contains no other transactions or derivative instruments.
VYNE Therapeutics Inc. reporting person David Domzalski, who serves as President and CEO and a Director, reported a transaction dated 09/30/2025. The filing shows 12,676 shares of common stock were disposed of under code F at a price of $0.335 per share; the form explains these shares were withheld by the issuer to satisfy tax withholding for vested restricted stock units. After the withholding, the reporting person beneficially owned 428,892 shares.
The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/02/2025. No derivative transactions are reported on this form and no other transactions or compensatory changes are disclosed.
Eventide Asset Management, LLC and two affiliated individuals filed an amendment on Schedule 13G disclosing beneficial ownership of 1,849,597 shares of VYNE Therapeutics common stock, representing 9.99% of the class based on 16,664,892 shares outstanding. The filing states these holdings reflect common stock issuable upon exercise of pre-funded warrants exercisable for up to 5,287,413 shares, but exercise is limited so the holder will not exceed 9.99%. The amendment explains the change was to disclose a different mix of security types and includes signatures dated August 14, 2025.
Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 1,370,938 shares of VYNE Therapeutics, representing 8.23% of the outstanding common stock. The reported position reflects shared voting and shared dispositive power only; the reporting persons state they have no sole voting or sole dispositive power over these shares.
The holding is reported as held by the Cormorant Funds, and the filing notes that Cormorant Global Healthcare Master Fund, LP has the right to receive dividends or sale proceeds for more than 5% of the shares. The percentage is calculated using 16,664,892 shares outstanding as reported by the issuer as of May 1, 2025. The reporting persons certify the shares are held in the ordinary course of business and not to influence control of the issuer.
VYNE Therapeutics furnished a press release reporting financial results for the quarter ended June 30, 2025; that press release is attached as Exhibit 99.1. The filing states the exhibit is being furnished and not "filed" for purposes of Section 18 of the Exchange Act. The report itself does not include the financial figures in this 8-K.
The registrant also disclosed that Christine Borowski, Ph.D. and Anthony Bruno resigned from the board effective immediately, each leaving their committee roles; the company stated the resignations were not due to any disagreement with the company or board and expressed thanks for their contributions.